抗血管生成治疗晚期NSCLC策略方案.pptVIP

谢 谢 ！ 血管通透性因子（vascular permeability factor,VPF） * IMC-IC11是一种正在研发的新药，只查到代号 参考文献1-贝伐作用机制 * Results: NSCLC enrollment completed 06/2009. As of 09/2009, 1,970 pts had median follow-up of 9.6 mo. The IRF reviewed BL scans of 1,881 pts; 1,470 (78%) had 1 BL measurable (meas) tumor ( 0.5cm) and 49% (718) were central; 67% had largest tumor size 3 cm; 14% had cavities and 10% had 1 cavity. BL tumor characteristics were generally similar across subpopulations (age 70, PS 2, pts with CNS mets). Pts with a history (Hx) of hemoptysis (n = 105) had more centrally located tumors, fewer numbers of meas tumor, and larger cavity size. There are 15 (0.8%) reported SPH events to date; 2 pts had no BL CT scan submitted and 2 pts with BL scans had no meas tumor (1 had Hx of hemoptysis). Of the remaining 11 pts with SPH: 8 had central tumors; 1 had cavitation (1.2 cm); 0 were on anticoagulants at BL; largest tumor size ranged from 1.8-11.6cm. There was 1 SPH in pts with 1 cavity (0.5%) and 8 in pts with central tumors (1.1%). * 参考文献8-2011肺出血共识-Ann Oncol-2011 Thoracic computed tomography images that show no clear vessel invasion by non-small-cell lung tumours. (A) Central tumour with infiltration of main carina and both main bronchi but no evident infiltration of large central blood vessels; (B) Central tumour with direct infiltration of the mediastinum but no clear infiltration of central blood vessels; (C) Central tumour touching without sign of pulmonary artery infiltration. The presence of an atelectasis makes the interpretation difficult and may necessitate multiplanar reconstructions to aid decision making. 咯血史的患者的出血风险较高，来自ARIES研究的数据 * 参考文献9-Sail Elderly-JTO-2012 * 参考文献9-Sail Elderly-JTO-2012 * 参考文献11-脑转移发生概况-JTO-2009；12-PASSPORT-JCO-2009 参考文献12-PASSPORT-JCO-2009 参考文献10-Meta分析-欧盟撤销脑转移禁忌症-Clin Cancer Res-2010 * 参考文献10-Meta分析-欧盟撤销脑转移禁忌症-Clin Cancer Res-2010 ATLAS研究入组了含经治CNS的患者 ，共730例患者入组，其中26患者为 CNS转移 ；因此C组 为141名CNS转移的患者 * 参考文献10-Meta分析-欧盟撤销脑转移禁忌症-Clin Cancer Res-2010 脑转